CMC Flexibility Still Needs an Evidence Plan
FDA's CMC flexibilities guidance for cell and gene therapy is not a lower quality standard. Learn how to document lifecycle decisions, comparability and platform knowledge, PPQ rationale, and post-approval commitments.
Flexibility is not a lower quality standard
Cell and gene therapy sponsors often face constraints that do not fit a conventional manufacturing playbook: small patient populations, limited lots, patient-specific production, complex analytical methods, short shelf lives, and rapidly developing process knowledge.
FDA’s May 2026 final guidance, Chemistry, Manufacturing, and Controls Flexibilities for Developing Human Cellular and Gene Therapy Products for a Biologics License Application, explains how CBER may apply scientific, risk-based flexibility within the existing statutory and regulatory framework.
The guidance is nonbinding and applies only to human cellular and gene therapy products regulated by CBER. It does not comprehensively define the CMC package needed for licensure, and FDA says sponsors should discuss their approach with the relevant review division before implementation.
That last point should shape how manufacturers use the document. Flexibility is not permission to defer difficult work without a plan. It is an opportunity to propose a justified path that protects product quality while evidence matures.
Use a lifecycle decision record
For each proposed flexibility, create a controlled decision record. State the conventional expectation, the constraint that makes it impractical or poorly suited, the alternative approach, the scientific and risk rationale, the evidence currently available, and the evidence that will be generated later.
The record should also define limits. Which product, process, site, method, or development phase does the decision cover? What assumptions must remain true? What result would invalidate the approach? Which FDA interaction documents the agency’s feedback?
This prevents a reasonable case-specific flexibility from quietly becoming an organizational default. It also gives quality, manufacturing, analytical development, and regulatory affairs a shared view of what is temporary, what is product-specific, and what must be revisited.
Four areas where evidence planning matters
1. Phase-appropriate controls during clinical development
FDA describes phase-appropriate CGMP and process-control strategies for investigational products. The guidance notes that process validation is not expected for investigational products, while recommending process-characterization work throughout development. It also discusses release acceptance criteria that mature as product knowledge increases.
Operationally, the sponsor should define what will be learned at each phase, who owns that learning, and when acceptance criteria become more specific. Before Phase 2 or 3 investigations, release tests must have predefined acceptance criteria. The development plan should make that transition visible rather than allowing early permissive limits to persist by inertia.
2. Risk-based comparability and prior knowledge
FDA recommends a risk assessment for manufacturing changes and says limited comparability data may be acceptable for a low-risk change to an investigational product when quality attributes are met and the change is submitted before the post-change product is administered.
The guidance also describes proposals to leverage knowledge across sufficiently similar products or critical components. That can include analytical methods, stability, specifications, comparability, and process-validation knowledge. Similarity must be demonstrated. For a platform analytical procedure, FDA may request product-specific verification when differences could affect method performance.
The evidence plan should therefore identify both the reusable platform element and the product-specific bridge. A claim of platform experience without a defined similarity assessment is not a control strategy.
3. A scientifically justified PPQ strategy
FDA says it does not specify a minimum number of PPQ batches in biologics licensing requirements or CGMP regulations. Sponsors should justify the number based on product and process understanding, manufacturing complexity, and the controls in place.
That flexibility makes the PPQ rationale more important, not less. The BLA should document the development studies, control strategy, and relevant experience from sufficiently similar products and processes. If production limits lead to a proposal for completing some PPQ activities after licensure or releasing PPQ batches, the protocol, criteria, distribution controls, and commitments need explicit governance.
4. Commercial specifications and analytical validation
When only a small number of lots exist at BLA submission, FDA may consider flexible approaches to initial commercial release specifications. The guidance also says that, when scientifically supported, an analytical method validation using a single representative lot may be considered.
These approaches require a plan for strengthening the evidence. FDA describes possible post-approval reevaluation of acceptance criteria as commercial experience grows, with specification changes submitted through the appropriate regulatory pathway. The quality system must retain the initial rationale, accumulate the new data, evaluate it on schedule, and trigger the required submission work.
Convert flexibility into commitments and triggers
Every flexibility should produce a small set of controlled commitments. Examples include completing additional PPQ activity, refining acceptance criteria after a defined number of commercial lots, adding real-time stability data, verifying a platform method for the specific product, or reassessing a comparability conclusion when a critical process parameter changes.
Give each commitment an owner, due condition, evidence location, review forum, and escalation route. Tie it to change control and management review where appropriate. A calendar date alone may be insufficient when the trigger depends on lot count, process experience, or enrollment.
Avoid describing a future activity only in regulatory correspondence. If operations cannot see the commitment, the organization may miss the point at which it becomes due.
Prepare for FDA engagement
Bring a decision-ready package to the relevant FDA interaction. Explain the constraint, the alternative, the supporting science, the remaining uncertainty, and the proposed mitigation. Show the lifecycle plan and ask focused questions that can produce actionable feedback.
Record FDA feedback and translate it into controlled actions. Separate an agency comment, a sponsor proposal, an agreed plan, and an internal recommendation. Those categories can blur when meeting minutes are summarized informally.
Early-stage teams can use IntelaSolve’s compliance readiness analysis to identify gaps in ownership and evidence planning. Established portfolios facing several cross-product CMC decisions may benefit from a focused strategy call.
The strongest flexible approach is still controlled
FDA’s guidance recognizes the real manufacturing constraints of cell and gene therapy development. It also repeatedly returns to scientific support, risk, product knowledge, case-specific justification, and early agency engagement.
Manufacturers should do the same. A flexible path is defensible when the current evidence, remaining uncertainty, future commitments, and decision authority are all visible. That is how flexibility supports development without weakening the quality story.
Map one proposed CMC flexibility from rationale through post-approval commitment in a focused IntelaSolve workflow evaluation, supported by a connected eQMS.